• The Park

    The Park

    Our values
    Testimonials
    Getting here
    2040 Vision

    See our plans to become a pioneering research and innovation district

    Learn More
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn More
  • Find a workspace
    R&D workspace

    Research and development workspaces for innovation and manufacturing

    Industrial space

    High-tech industrial units now available in Oxfordshire

    Lab space

    Fitted or unfitted laboratory space in Oxfordshire

    Co-working office space at Bee House

    Welcome to Oxfordshire’s largest and buzziest co-working space

    Serviced office space

    Flexible office space for agile businesses in Oxfordshire

    Office space

    Readily available office spaces for companies of all sizes

    Amenity space

    Food & beverage, retail and leisure spaces, including the new Signal Yard development.

    Meeting and conference space

    Available for both Milton Park occupiers and off-park companies to hire.

    Design and build

    Looking for landmark laboratory, flagship head office or bespoke R&D workspace? We can help…

    Learn more
    Future developments

    Discover future developments at Milton Park including Nebula and Signal Yard

    Learn more
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more
  • Community
    Signal Yard

    17 state-of-the-art units offering a vibrant mix of food & beverage, retail and leisure venues

    Learn more

    Community

    Community
    Signal Yard
    Amenities
    Who's here
    Find a job
    Meeting and Conference Space

    Available for both Milton Park occupiers and off-park companies to hire

    Learn more
  • News
  • Events
  • About us
    Getting here

    Milton Park has unrivalled transport links by bus, train, bike and road.

    Learn more

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
  • The Park
    back

    The Park

    back

    The Park

    Our values
    Testimonials
    Getting here

    2040 Vision

    Getting here

  • Find a workspace
    back

    Find a workspace

    Search by type

    back

    Search by type

    R&D workspace
    Industrial space
    Lab space
    Co-working office space at Bee House
    Serviced office space
    Office space
    Amenity space
    Meeting and conference space

    Design and build

    Future developments

    Signal Yard

  • Community
    back

    Community

    back

    Community

    Community
    Signal Yard
    Amenities
    Who's here
    Find a job

    Meeting and Conference Space

  • News
    back

    News

  • Events
    back

    Events

  • About us
    back

    About us

    About us
    Meet the team
    Local engagement
    Sustainability
  • Contact
    back

    Contact

HomeNewsOccupier News

Occupier News

22 January 2026

Innovation Community News – January 2026

Back to results

January 2026 innovation news

A summary of recent news and announcements from Milton Park-based companies:

  • Evotec reaches milestone in fight against Alport Syndrome 
  • LIO featured in The Sunday Times 100 Tech 2026 
  • Nium launches new deep-tech materials platform, LAYRR 
  • Recursion reports positive trial data for FAP treatment 
  • Tokamak Energy takes another step forward towards fusion  

 

Evotec reaches an important milestone in fight against Alport Syndrome 

Evotec, an occupier pioneering the future of drug discovery and preclinical development, has reached an important milestone in its fight against Alport Syndrome, with its first patient having received treatment in its Phase 2 clinical trial alongside its partner, Bayer. 

The life science company’s trial, which commenced in December 2025, is investigating potential treatments for Alport Syndrome, a rare genetic condition characterised by kidney disease, hearing loss and eye abnormalities.  

With most affected individuals experiencing progressive loss of kidney function, which can lead to end-stage kidney disease, the trial marks an important step in finding a life-changing treatment for the condition. 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very pleased that our jointly developed antibody, BAY 3401016, for the treatment of Alport syndrome has advanced into Phase 2 of clinical development.  

“The initiation of this study represents an important and hopeful step forward. We congratulate Bayer on the Phase 2 launch and are proud to support the advancement of this program. 

 

LIO featured in The Sunday Times 100 Tech 2026 list 

LIO, which use monitoring and observational technology for mental health care, has been named in The Sunday Times’ list of the UK’s fastest growing private tech companies. 

Based here at Milton Park, the occupier ranked number 34 in the UK the Hardware/other category, reporting 48.6% annual sales growth over the last three years. 

Coinciding with the award, the occupier also hit a significant company milestone, surpassing 100 million hours of inpatient mental health care across its partner facilities. 

 

Nium launches new deep-tech materials platform, LAYRR 

Nium, a Milton Park occupier researching the decarbonisation and decentralisation of the global ammonia supply chain using nanotechnology, has launched a new deep-tech materials platform, LAYRR. 

The platform will enable atomic-level surface engineering, turning “impossible” materials that have only existed in AI simulations into reality.  

LAYRR’s atomic surface engineering will support the development of a vast range of technologies, including magnets, batteries, high entropy alloys and additive manufacturing. 

 

Recursion reports positive trial data for FAP treatment 

AI drug discovery company, Recursion (formerly Exscientia), has announced positive data from its TUPELO trial, which is investigating therapies for familial adenomatous polyposis (FAP). 

FAP is one of the most clinically significant hereditary bowel cancer syndromes. If left untreated, it carries a near 100% risk of developing colorectal cancer before the age of 40. 

In the Phase 2 portion of the study, the inhibitor (REC-4881) demonstrated rapid and durable reductions in polyp burden, a significant step forward in FAP treatment. 

Chris Gibson, Co-Founder and CEO of Recursion, commented: “This is a powerful example of how even the earliest versions of the Recursion OS can uncover therapeutic opportunities in diseases with no approved pharmacotherapy options. And since this discovery, we’ve only added to the breadth, depth, and power of the Recursion OS; we believe this is the first of many potential medicines that will advance as our flywheel of discovery accelerates.” 

 

Tokamak Energy takes another step forward towards fusion  

Tokamak Energy, an occupier working on the development and delivery of fusion energy, has taken another step towards making the technology a reality, after successfully generating Radio Frequency (RF) power using its gyrotron. 

A gyrotron works by accelerating a beam of electrons through an interaction region where they emit microwave radiation, which is transmitted through a waveguide into the plasma. 

This is the first time all systems have operated together, validating the huge effort to integrate the complex electrical, control and water systems. 

Once fully commissioned on the world’s highest field spherical tokamak, the gyrotron will generate 1 MW of RF power to heat the plasma and drive its current. 

Who’s here?

Click to learn more

Related stories

Wellness classes at Milton Park with Hester

22 January 2026

Sometimes, all you need is a nice break to refresh your mind and body. At Milton Park, we work alongside Hester to offer our occupiers the chance to get back to nature and improve their wellbeing – all in the space of a lunch break.

Read more

Get rewarded for greener travel

16 January 2026

Oxfordshire County Council has partnered with BetterPoints to use their app to run a free rewards challenge for anyone who lives, works or studies in Oxfordshire.

Read more

Benedicts joins CBRE as joint agents

12 January 2026

Milton Park has appointed Benedicts to join CBRE as joint leasing agents to support on helping existing occupiers with their evolving space needs and to attract new occupiers to the Park.

Read more

Sign up to our newsletter

Subscribe

Subscribe to the Milton Wonder newsletter for latest news, events and competitions.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
What best describes your relationship with Milton Park?*
Please select all that apply
Consent*

We’re here to help
Call us on +44 (0)1235 865 555

Or follow
us on
  • Privacy Policy
  • Cookie Preferences

®Milton Park is a registered trademark, owned by MEPC Milton GP Limited, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire OX14 4SB

Registered Office: MEPC Milton GP Ltd, Sixth Floor, 150 Cheapside, London EC2V 6ET

Registered in England, No. 7669538 | ® Copyright MEPC Milton GP Ltd 2025